Essenlix Corporation, a developer, manufacturer, and provider of mobile instant health test solutions for both personal and clinical use, announced that Essenlix, in partnership with Roche Norway, has won Norway Østfold Hospital System’s patient at-home testing solution Innovation Partnership that will use Essenlix’s iMOST as the test platform.

Østfold Hospital selected the winner of the Patient At-Home Test Innovative Partnership through an open public bidding process, participated in by about 10 company teams, including some of the world’s major diagnostic companies, and reviewed by multidisciplinary committee of experts in diagnostics, laboratory medicine, medicine, patientcare, technology, e-health, and other fields.

The Innovation Partnership will “develop user-friendly, innovative and quality-assured devices/instruments and services that contribute to safe patient sampling and analysis even at home.” The patient at-home testing solution partnership has a 12-month development phase funded by Østfold Hospital, followed by the hospital’s purchase phase.

“This is a very innovative and exciting project. We strongly believe that such a solution can be of great value to the patient in everyday life,” says Anne Eva Bjerke, head of section at the Centre for Laboratory Medicine of Østfold Hospital, a member of Østfold Hospital project selection committee, and the manager of the project.

The winning bid by the Roche Norway, Essenlix, and Diffia team, led by Roche, offered the [email protected] solution, which uses Essenlix’s iMOST platform as the test instrument/device to be used by patients at home and delivers test results to doctors and hospitals via the cloud, utilizing the software that will be jointly developed by Essenlix, Diffia, and Roche, as well as Roche’s IT, QC and other expertise.

“We are delighted to be part of providing such an important healthcare diagnostic solution, which has the potential to revolutionize current medical practice,” says Dieter Weinand, executive chairman of Essenlix.

Essenlix iMOST (instant Mobile Self-Test) is an instant, mobile phone-based health test platform for both personal and clinical use. iMOST is designed to allow a person to perform many diagnostic/health tests on themselves, accurately, anywhere, anytime, using a single drop of body fluid and a smartphone, within about 60 seconds, with the result sent immediately to professionals.

iMOST allows for a single instrument to perform health test for many sample types (blood, saliva, urine, swabs, sputum, breath, mucus, tissues, etc.) and for many assay types (immunoassay, colorimetric assay, cytology and pathology, nucleic acid assay, etc.). 

Essenlix is an integrated company with design, development, prototyping, and manufacturing all in-house. Essenlix has developed and built unique manufacturing lines with a capacity of over 10 million iMOST test cards per year.

“We are very proud to have been selected by Roche Norway as its partner and to win the Innovation Partnership.  Both are further validation of the innovation and uniqueness of Essenlix’s iMOST platform,” says Stephen Y. Chou, PhD, MA, BS, founder and co-chairman of Essenlix. “The Patient At-Home Test Partnership is an excellent vehicle to further demonstrate the capabilities of the Essenlix iMOST platform for both, clinical and personal use. This is an important step forward to making the iMOST platform a solution to the unmet need of instant personal health testing and providing a key missing link between personal health, remote monitoring and treatment, and e-health services.

Featured image: Essenlix’s iMOST Instant Mobile Self-Test. Photo: Essenlix